SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like New SARS-CoV-2 KP.2 variant defies vaccines with higher spread, study warns April 29, 2024 Study investigates ambiguities in ICD coding for respiratory infections January 27, 2025 Psilocybin reconfigures brain networks, showing potential for lasting therapeutic effects July 18, 2024
Psilocybin reconfigures brain networks, showing potential for lasting therapeutic effects July 18, 2024